Core Insights - ProQR Therapeutics is set to present its Axiomer RNA editing technology at two significant scientific conferences in May 2025, showcasing its potential in transforming RNA therapies [1][2] Conference Presentations - ProQR will participate in the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting from May 13-17, 2025, in New Orleans, Louisiana, featuring both oral and poster presentations [3][4] - The company will also present at the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference from May 19-22, 2025, in San Diego, California, with podium presentations [5] Presentation Details - Key presentations include: - "ADAR-Mediated RNA Editing of SLC10A1(NTCP) as a Therapeutic Approach to Reduce Liver Bile Acid Re-Uptake in Cholestatic Diseases" on May 16, 2025 [6] - "ADAR-Mediated RNA Editing-Based Correction of PNPLA3 I148M Functionality to Address Hepatic Steatosis" on May 15, 2025 [6] - "ADAR-Mediated RNA Editing of Premature Termination Codon Results in Functional Correction in MECP2 for Rett Syndrome" on May 15, 2025 [6] - "Advancing Axiomer ADAR RNA Editing Platform - Editing oligonucleotides optimization for therapeutic use" on May 22, 2025 [6] Axiomer Technology Overview - Axiomer™ is a next-generation RNA base editing technology that utilizes ADAR (Adenosine Deaminase Acting on RNA) to make specific single nucleotide edits in RNA, potentially leading to new classes of medicines for various diseases [8][9] - The technology aims to correct disease-causing mutations and modulate protein expression, addressing both rare and prevalent diseases with unmet medical needs [9]